Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
BURLINGTON, Mass. , June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference .
View HTML
Toggle Summary Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
BURLINGTON, Mass. , June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews , M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021 . "Will brings an impressive combination of medical, clinical,
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
View HTML
Toggle Summary Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
BURLINGTON, Mass. , June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
View HTML
Toggle Summary Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
BURLINGTON, Mass. , May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
View HTML
Toggle Summary Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
Flexion reported ZILRETTA ®  (triamcinolone acetonide extended-release injectable suspension) net sales of $24 .6 million David Arkowitz , CFO, stepping down effective May 31,2021 , and will be succeeded by Fred Driscoll New data presented at ASGCT indicate the low dose of FX201 provided durable
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , May 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
View HTML
Toggle Summary Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021
BURLINGTON, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, May 12, 2021 . A live webcast of the conference call can be accessed
View HTML
Toggle Summary Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Findings from a Phase 1 single ascending dose trial indicate the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis (OA), was generally well-tolerated Two of five patients (40%) treated with FX201 in the low-dose, single ascending dose cohort reported substantial
View HTML
Toggle Summary Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021
First-quarter ZILRETTA® net sales estimated to be approximately $24 .6 million 2021 full-year ZILRETTA net sales anticipated to be in the range of $120 million to $130 million and total operating expenses expected between $195 million to $205 million Company to hold conference call today at 4:30
View HTML